{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:06:19Z","timestamp":1767837979714,"version":"3.49.0"},"reference-count":14,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>(1) Background: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis of unknown etiology. Coronavirus disease 2019 (COVID-19) vaccines can cause a variety of adverse cutaneous manifestations. PG associated with mRNA vaccines has not previously been described. This case study reports on the first patient to develop PG after receiving BNT162b2. (2) Case Presentation: An otherwise-healthy 27-year-old man developed multiple skin lesions 24 h after receiving the first dose of the messenger RNA-based Pfizer\/BioNTech BNT162b2 COVID-19 vaccine. When in hospital, he developed a new painful ulcerative lesion on his right hand. Skin ulcer edge biopsy showed severe epidermal neutrophilic infiltrate with epidermal and dermal edema, underlying superficial dermal necrosis, and characteristic undermining with extensive mixed inflammatory infiltration of the dermis and abscess formation consistent with an ulcer with mixed dermal inflammation compatible with pyoderma gangrenosum. The lesion showed rapid improvement after the initiation of immunosuppressive therapy. (3) Conclusions: PG may be a rare adverse event related to the BNT162b2 vaccine, which could be more frequently encountered with the wide-scale use of mRNA vaccines. The continuous monitoring and surveillance of skin manifestations post-vaccination is essential.<\/jats:p>","DOI":"10.3390\/vaccines10010087","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T23:35:09Z","timestamp":1641771309000},"page":"87","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-007X","authenticated-orcid":false,"given":"Mazin","family":"Barry","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz","family":"AlRajhi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-3155","authenticated-orcid":false,"given":"Khaldoon","family":"Aljerian","sequence":"additional","affiliation":[{"name":"Department of Pathology, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e71974","DOI":"10.7554\/eLife.71974","article-title":"Mortality: A comprehensive look at the COVID-19 pandemic death toll","volume":"10","author":"Simonsen","year":"2021","journal-title":"eLife"},{"key":"ref_2","first-page":"1663","article-title":"COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.clindermatol.2021.07.011","article-title":"The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin","volume":"39","author":"Magro","year":"2021","journal-title":"Clin. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/ced.14819","article-title":"Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination","volume":"46","author":"Ramessur","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Baffa, M.E., Maglie, R., Giovannozzi, N., Montefusco, F., Senatore, S., Massi, D., and Antiga, E. (2021). Sweet Syndrome Following SARS-CoV2 Vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9111212"},{"key":"ref_9","unstructured":"Vashisht, P., Bansal, P., Goyal, A., and Holmes, M.P.H. (2021, September 14). Sweet Syndrome, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK431050\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"652470","DOI":"10.3389\/fimmu.2021.652470","article-title":"Neutrophils in COVID-19","volume":"12","author":"Reusch","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"680134","DOI":"10.3389\/fimmu.2021.680134","article-title":"Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets","volume":"12","author":"Hazeldine","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: Modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/20009666.2021.1958492","article-title":"Pyoderma gangrenosum following COVID-19 infection","volume":"11","author":"Syed","year":"2021","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-4632.2009.03897.x","article-title":"Neutrophilic dermatosis of the hands after influenza vaccination","volume":"48","author":"Wolf","year":"2009","journal-title":"Int. J. Dermatol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/1\/87\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:36:37Z","timestamp":1760362597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/1\/87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["vaccines10010087"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10010087","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]}}}